The ADA 2026 Sessions Dropped Five Simultaneous Phase 3 Readouts
The 86th American Diabetes Association Scientific Sessions in New Orleans (June 2026) delivered something unprecedented: Phase 3 data for five separate GLP-1-adjacent drug programs presented in the same week, several published simultaneously in peer-reviewed journals. For patients and clinicians, this represents the clearest picture yet of where GLP-1 therapy is heading over the next 12-18 months.
Here is what each program means for your treatment options — and which ones your doctor should be tracking.
1. Orforglipron (Eli Lilly) — Already Here
FDA-approved April 1, 2026, for weight management. This is the first non-peptide, small-molecule oral GLP-1. The ACHIEVE trials presented at ADA 2026 showed strong results in type 2 diabetes specifically (the weight-loss approval came from earlier ATTAIN data). Key advantage: no food, water, or timing restrictions. $149/month cash-pay at launch. Still being studied for diabetes indication and cardiovascular outcomes. The diabetes-specific data from ACHIEVE-2, ACHIEVE-3, and ACHIEVE-5 were published simultaneously in The Lancet and JAMA.
2. Retatrutide (Eli Lilly) — The Triple Agonist
Retatrutide targets three receptors: GLP-1, GIP, and glucagon. This is the most aggressive multi-target approach in late-stage development. Early Phase 2 data showed up to 24% weight loss at 48 weeks; the Phase 3 data presented at ADA 2026 confirmed the signal across larger populations. The addition of glucagon receptor activity may increase energy expenditure — a mechanism that GLP-1-only and GLP-1/GIP dual drugs do not provide. Not yet FDA-approved; submission expected in late 2026 or early 2027.
3. CagriSema (Novo Nordisk) — Semaglutide Plus Amylin
CagriSema combines once-weekly semaglutide (2.4mg) with cagrilintide, an amylin analog. The three REIMAGINE trials, published simultaneously in The Lancet Diabetes & Endocrinology, met primary endpoints for A1C reduction and confirmed weight loss across diverse type 2 diabetes populations. A February 2026 head-to-head comparison showed Lilly's Zepbound produced 25.5% average weight loss versus CagriSema's 23% at 84 weeks — giving tirzepatide the numerical edge. Novo Nordisk has filed with the FDA for a weight-loss indication; U.S. launch is targeted for early 2027.
4. Survodutide (Boehringer Ingelheim) — The Liver Play
Survodutide is a dual GLP-1/glucagon agonist with a particularly interesting secondary target: metabolic dysfunction-associated steatohepatitis (MASH), the liver disease formerly known as NASH. Phase 2 data showed meaningful liver fat reduction alongside weight loss. This could make survodutide the first GLP-1-class drug specifically positioned for liver disease. Phase 3 trials are ongoing.
5. Elecoglipron (AstraZeneca) — The New Oral Contender
AstraZeneca entered the GLP-1 race with elecoglipron, an oral small-molecule GLP-1 receptor agonist that just advanced to Phase III. In the VISTA trial (310 patients with obesity), the 75mg dose produced clinically meaningful weight loss. In SOLSTICE (404 patients with type 2 diabetes), 90% of patients on elecoglipron reached an A1C under 7%. Both trials were published in The Lancet concurrent with ADA 2026 presentations. This adds a third oral option to the pipeline behind Wegovy pill and orforglipron.
What This Means for You Now:
You do not need to wait for next-generation drugs to start treatment. The medications available today — semaglutide, tirzepatide, orforglipron — are already highly effective. But if you are a partial responder or are interested in emerging options, knowing the pipeline helps you have informed conversations with your prescriber about timing and switching strategies.
A Timeline for Your Doctor
| Drug | Status (June 2026) | Expected Availability | Key Differentiator |
|---|---|---|---|
| Orforglipron | FDA-approved (April 2026) | Available now | Oral, no food restrictions |
| Wegovy HD 7.2mg | FDA-approved (March 2026) | Available now | Highest semaglutide dose |
| CagriSema | FDA filing submitted | Early 2027 | First GLP-1 + amylin combination |
| Retatrutide | Phase 3 complete | Late 2027 | Triple agonist (GLP-1/GIP/glucagon) |
| Survodutide | Phase 3 ongoing | 2027-2028 | Liver disease (MASH) target |
| Elecoglipron | Entering Phase 3 | 2028+ | Third oral GLP-1 option |
Start with What's Available Today
Current GLP-1 medications already deliver strong results. Compare licensed providers to find the right starting point for your treatment.
Compare Providers →